Literature DB >> 30128018

Silencing of uPAR via RNA interference inhibits invasion and migration of oral tongue squamous cell carcinoma.

Xuexiang Gao1, Qi Guo1, Shuo Wang1, Cen Gao1, Jian Chen2, Li Zhang1, Yuan Zhao1, Jing Wang1.   

Abstract

Overexpression of urokinase-type plasminogen activator receptor (uPAR) has been implicated in promoting tumor invasion in various cancer types, including oral tongue squamous cell carcinoma (OTSCC); therefore, the effect of suppressing uPAR expression on the invasive and metastatic potential of OTSCC was investigated. A total of 65 paraffin-embedded tissues were obtained from patients with OTSCC. Immunohistochemistry was used to determine the expression level of uPAR. The Ts cells transfected with short hairpin RNA targeting uPAR were constructed and validated. The cells were used in a number of in vitro analyses, including migration, invasion and western blot analysis assays. Furthermore, a mouse lung metastatic model was used to detect the metastatic ability of OTSCC cells in the lungs. OTSCC cell metastasis and relapse were determined to be associated with uPAR immunopositivity. Inhibition of uPAR expression in Ts cells demonstrated a 40% decrease in migration and a 60% decrease in invasion in vitro, with an associated downregulation of matrix metalloprotease (MMP)-2, MMP-9 and phosphorylated extracellular signal-regulated kinase. In vivo analysis indicated a 90% decrease in the number of mice bearing macroscopic lung metastases. In conclusion, the present study demonstrated that the targeting of uPAR-inhibited cellular proliferation and invasion would provide a potential treatment for OTSCC in the future.

Entities:  

Keywords:  RNA interference; invasion; migration; oral tongue squamous cell carcinoma; urokinase-type plasminogen activator receptor

Year:  2018        PMID: 30128018      PMCID: PMC6096076          DOI: 10.3892/ol.2018.9094

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  33 in total

Review 1.  Global epidemiology of oral and oropharyngeal cancer.

Authors:  Saman Warnakulasuriya
Journal:  Oral Oncol       Date:  2008-09-18       Impact factor: 5.337

2.  MEK/ERK inhibitor U0126 increases the radiosensitivity of rhabdomyosarcoma cells in vitro and in vivo by downregulating growth and DNA repair signals.

Authors:  Francesco Marampon; Giovanni Luca Gravina; Agnese Di Rocco; Pierluigi Bonfili; Mario Di Staso; Caterina Fardella; Lorella Polidoro; Carmela Ciccarelli; Claudio Festuccia; Vladimir M Popov; Richard G Pestell; Vincenzo Tombolini; Bianca Maria Zani
Journal:  Mol Cancer Ther       Date:  2011-01       Impact factor: 6.261

Review 3.  Regulatory networks defining EMT during cancer initiation and progression.

Authors:  Bram De Craene; Geert Berx
Journal:  Nat Rev Cancer       Date:  2013-02       Impact factor: 60.716

Review 4.  Clinical applications of the urokinase receptor (uPAR) for cancer patients.

Authors:  Martin C Boonstra; Hein W Verspaget; Sjam Ganesh; Frank J G M Kubben; Alexander L Vahrmeijer; Cornelis J H van de Velde; Peter J K Kuppen; Paul H A Quax; Cornelis F M Sier
Journal:  Curr Pharm Des       Date:  2011       Impact factor: 3.116

5.  SB365 inhibits angiogenesis and induces apoptosis of hepatocellular carcinoma through modulation of PI3K/Akt/mTOR signaling pathway.

Authors:  Sang-Won Hong; Kyung Hee Jung; Hee-Seung Lee; Myung-Joo Choi; Mi Kwon Son; Hong-Mei Zheng; Soon-Sun Hong
Journal:  Cancer Sci       Date:  2012-09-25       Impact factor: 6.716

6.  [Construction of shRNA expression vector pWH1 and its function in silencing the HIF1 gene].

Authors:  Yuan-ming Wu; Xiao-nan Zhang; Zhe-yi Han; Chun-ying Li; Nan-chun Chen
Journal:  Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi       Date:  2008-02

7.  Overexpression of integrin αv facilitates proliferation and invasion of oral squamous cell carcinoma cells via MEK/ERK signaling pathway that is activated by interaction of integrin αvβ8 with type Ⅰ collagen.

Authors:  Yasutaka Hayashido; Hisataka Kitano; Taishi Sakaue; Takahiko Fujii; Mirei Suematsu; Shigeru Sakurai; Tetsuji Okamoto
Journal:  Int J Oncol       Date:  2014-09-04       Impact factor: 5.650

8.  Western blot: technique, theory, and trouble shooting.

Authors:  Tahrin Mahmood; Ping-Chang Yang
Journal:  N Am J Med Sci       Date:  2012-09

9.  The receptor for urokinase-plasminogen activator (uPAR) controls plasticity of cancer cell movement in mesenchymal and amoeboid migration style.

Authors:  Francesca Margheri; Cristina Luciani; Maria Letizia Taddei; Elisa Giannoni; Anna Laurenzana; Alessio Biagioni; Anastasia Chillà; Paola Chiarugi; Gabriella Fibbi; Mario Del Rosso
Journal:  Oncotarget       Date:  2014-03-30

Review 10.  Role of urokinase receptor in tumor progression and development.

Authors:  Hyangsoon Noh; Sungguan Hong; Shuang Huang
Journal:  Theranostics       Date:  2013-06-25       Impact factor: 11.556

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.